402 related articles for article (PubMed ID: 34743319)
1. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME
Clin Pharmacol Ther; 2022 Apr; 111(4):886-895. PubMed ID: 34743319
[TBL] [Abstract][Full Text] [Related]
2. Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
[TBL] [Abstract][Full Text] [Related]
4. No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial.
Knorr U; Koefoed P; Soendergaard MH; Vinberg M; Gether U; Gluud C; Wetterslev J; Winkel P; Kessing LV
Acta Neuropsychiatr; 2016 Apr; 28(2):101-9. PubMed ID: 26573431
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
6. Increased global integration in the brain after psilocybin therapy for depression.
Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
[TBL] [Abstract][Full Text] [Related]
7. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
9. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.
Becker AM; Klaiber A; Holze F; Istampoulouoglou I; Duthaler U; Varghese N; Eckert A; Liechti ME
Int J Neuropsychopharmacol; 2023 Feb; 26(2):97-106. PubMed ID: 36342343
[TBL] [Abstract][Full Text] [Related]
10. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial.
Brunoni AR; Carracedo A; Amigo OM; Pellicer AL; Talib L; Carvalho AF; Lotufo PA; Benseñor IM; Gattaz W; Cappi C
Braz J Psychiatry; 2020 Apr; 42(2):128-135. PubMed ID: 31721892
[TBL] [Abstract][Full Text] [Related]
11. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.
Holze F; Becker AM; Kolaczynska KE; Duthaler U; Liechti ME
Clin Pharmacol Ther; 2023 Apr; 113(4):822-831. PubMed ID: 36507738
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram continuation treatment prevents relapse of depressive episodes.
Rapaport MH; Bose A; Zheng H
J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
[TBL] [Abstract][Full Text] [Related]
14. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
Szigeti B; Weiss B; Rosas FE; Erritzoe D; Nutt D; Carhart-Harris R
Psychol Med; 2024 Jun; 54(8):1717-1724. PubMed ID: 38247730
[TBL] [Abstract][Full Text] [Related]
15. [Psilocybin compared with escitalopram for depression].
Strous JFM
Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35138714
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.
Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR
Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056
[TBL] [Abstract][Full Text] [Related]
19. [The use of psilocybin for treatment-resistant depression].
Johannesdottir A; Sigurdsson E
Laeknabladid; 2022 Sep; 108(9):403-410. PubMed ID: 36040772
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
